Index based investment using a company's total stock market value is a great concept and indexes such as the S&P 500 generally provide solid low cost diversification. Unfortunately, Wall Street has now applied this concept to "sectors" of the stock market without adjusting for the size of individual companies. This is not only exposing investors … Continue reading MSCI Health Care Index: A Good Measure or a Pyramid Scheme Enabler? Case Study: Johnson and Johnson and Pfizer
Doris is 85 and suffers from moisture build up in her eye, what some call wet eye. She is on Medicare and gets treated with Eylea, a Regeneron product, every 4-5 weeks. Each treatment costing $6,200. That is more than $70,000 per year even though Doris never made more than $40,000 while working. … Continue reading Regeneron’s Eylea: Pulling Open the Curtain on Drug Costs
Senator McConnell's Dilemma: To Serve Patients or Investors? When evaluating health care investments it is important to analyze the structure of leading drug and medical equipment companies. A close look indeed reveals a derivative driven system in which private equity and hedge funds increase demand for drug payments by purchasing the rights … Continue reading Is Patient Health Being Mortgaged via Derivatives as Homes Were During the Financial Crisis?
Disclosure and Media Development Background: Parish & Company maintains no speculative investments in the health care companies discussed and does not collaborate with any private equity or hedge funds. It's goal is to identify high quality health care opportunities suitable for long term oriented investment. This effort includes providing high quality news material to leading … Continue reading Private Equity and Hedge Funds Employ Enron’s Tricks to Manipulate Health Care Grid